HAD 4

General

Cell Line

hPSCreg name HADe004-A
Cite as:
HADe004-A (RRID:CVCL_C075)
Alternative name(s)
HAD 4
Cell line type Human embryonic stem cell (hESC)
Similar lines No similar lines found.
Last update 14th April 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Hadassah University Hospital (HAD)
Owner Hadassah Human Embryonic Stem Cell Research Center
Distributors
Derivation country Israel

External Databases

Cellosaurus CVCL_C075
BioSamples SAMEA6613187
Wikidata Q54872333

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Synonyms
  • Riley-Day Syndrome
  • HSAN 3
  • Neuropathy, Hereditary Sensory and Autonomic, Type III
  • Hereditary Sensory and Autonomic Neuropathy Type III
  • Familial Dysautonomia
  • HSAN III
  • Riley- Day
  • Familial dysautonomia
  • hereditary sensory and autonomic neuropathy type III
show more synonyms
Genetic variants
ELP1 (target)
Homozygous
Sequence variation: Homozygous for ELP1 c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); splice donor mutation (PubMed=26437462)

External Databases (Donor)

BioSamples SAMEA6613348

Ethics

Was the embryo established purely for research purposes? No
Have both parents consented to the use of the embryo for ESC derivation? Yes
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Hadassah IRB Committee
Approval number 16-23.04.04
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? No

hESC Derivation

Date of derivation 2006-02-24
Supernumerary embryos from IVF treatment?
No
Other hESC source: IVF
PGD Embryo?
Yes
Derived under xeno-free conditions?
No
Derivation under GMP?
No
Available as clinical grade?
No

Culture Conditions

Feeder cells foreskin
O2 Concentration 4 %
CO2 Concentration 5 %

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
POU5F1 (OCT-4)
Yes
SSEA-3
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
TUBB3
Yes
SOX17
Yes
desmin
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro directed differentiation
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro directed differentiation
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro directed differentiation

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY

Other Genotyping (Cell Line)